DOCSLIB.ORG

Annual Report and Accounts 2012 – 2013 Annual Report and Accounts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report and Accounts 2012 – 2013 Annual Report and Accounts Annual Report and Accounts 2012 – 2013 Annual Report and Accounts Welcome to our Annual Report and Accounts for 1 April 2012 – 31 March 2013 We have written this year’s report Contents to be as accessible to as many About us 3 people as possible. In the first half Chair and Director’s letter 4 of the report, we have included Highlights of the year 5 an overview of our achievements Health service development 6-8 in this year and our plans for the Rare diseases 9 future. In the second half of the Information and support 10 report is the trustees’ report, our Championing biomedical science 11 financial statements and accounts Access to medicines 12 Working in Europe 13 for the year. Looking ahead to 2013 - 2014 14 Trustees’ annual report 15-16 Treasurer’s letter and financial review 17 Independent auditor’s report 18-19 Statement of financial activities 20 Balance sheet 21 Notes to the financial statements 22-28 Acknowledgements 29 Membership 30-31 2 Genetic Alliance UK Genetic Alliance UK About us There are over Genetic Alliance UK is the We are the only organisation in national charity of over the UK that provides a voice for all 6,000 160 patient organisations patients and families affected by genetic conditions on a European, UK different genetic supporting all those affected by and devolved nation level. genetic conditions. Our aim is conditions to improve the lives of people About genetic conditions affected by genetic conditions, Genetic conditions are life-long ensuring that high quality and serious illnesses, affecting 4 out of every services and information are multiple systems of the body. Many S are progressive, meaning affected E available to all who need them. I individuals lose their health, quality of B What we do life and may die prematurely. Currently, A few genetic conditions can be cured, B Supporting: We seek to raise and few have effective treatments; but 100 born in the UK have awareness of genetic conditions and all individuals and their families need improve the quality of services and appropriate care and support, as well a genetic condition information available to patients and as timely and accurate diagnosis. families. Patients and families with genetic Campaigning: We actively campaign conditions often have a high level of on behalf of those with genetic unmet need. conditions on issues of policy and It is vital that medical research sheds light 6 out practice to influence governments, on these conditions in order to develop policy makers, industry and care effective interventions and therapies and providers such as the NHS. that they are made available to patients of 10 PEOPLE Uniting: We provide a united voice as soon as possible, with appropriate for all those affected by genetic care and support, to improve health and are likely to develop a conditions, enabling us to work save lives. disease that is partially together towards the common goal genetically determined of making life better for patients and families at risk. by the age of 60 Annual Report and Accounts 2012 - 2013 3 From the Chair and the Director Letter from the Chair and the Director 2012 – 2013 has been a very busy Other noteable achievements this year for us, and we are proud of our year include we were one of the work and our achievements. first patient groups to sign up to the AllTrials campaign calling on We are particularly proud that we greater transparency for clinical trial influenced and campaigned for data. We were runners up in the changes within the reorganisation GlaxoSmithKline and King’s Fund of commissioning NHS specialised IMPACT awards this year, meaning services in England, and supported we were in the top 20 charities from our member groups to be centrally over 400 entries. It is great to receive involved in shaping the services for recognition of our work and our their own conditions. efforts. We are delighted to have published Finally, we are now an alliance of Christopher J Friend our Route Maps Toolkit this year. Route 162 patient groups, uniting those Chair Maps can improve information as well affected by genetic conditions across as coordination of health and social the UK. Our aim is to keep growing care for people with rare genetic our membership numbers, and to keep conditions, and the Toolkit will enable improving how we work with our patient groups to devise their own members. condition-specific Route Map, which in turn will support many more patients Looking ahead, next year promises and families. to be a busy and exciting year. We look forward to working actively with This year saw the Scottish Government members, supporters and friends as announce the creation of a ‘Rare we continue to Support, Campaign Disease Drug Fund’. It followed a and Unite on behalf of all those great deal of work in partnership with affected by or at risk from genetic other organisations and many of our disorders. We thank our members and Alastair Kent member groups and families based in all our partners for your support, and Director Scotland. We look forward to seeing we look forward to working with you the initiative providing medicines that in 2013 - 2014. will help many people. 4 Genetic Alliance UK Highlights of the year Highlights of the year • Earl Howe, Minister for Health • Our membership on the Ethics & • Charity of the Year at announcing the establishment of the Governance Team on the Prime Genzyme Haverhill Rare Disease Stakeholder Forum at Minister’s 100,000 genome project • 162 member groups – our parliamentary reception • Two SWAN UK family days our largest number ever • Publication of a fair and equitable for families of children with • The Scottish Government All-England Commissioning undiagnosed genetic conditions announcing the creation of a Policy for preimplantation • 350,000 unique visitors to ‘Rare Disease Drug Fund’ genetic diagnosis our websites • 0.8k Investment income • 112.8k Voluntary income Income 571.4k • 721k • 36k Other Charitable activities • 39.6k Expense Governance 613.6k • 678.5k • 25.3k Charitable Generating activities voluntary income Annual Report and Accounts 2012 - 2013 5 Health service development Health service development Genetic Alliance UK advocates We also responded to the Children To support patients, families and for improved health services, and Young People’s Health Outcomes patient groups in responding to the we support the acceleration Framework. We drew on the real-life Clinical Reference Groups’ Service experiences of families of children Specifications and Commissioning of scientific innovations into with undiagnosed genetic conditions Policies public consultation, we healthcare that will make a around issues of communication, produced free webinars full of helpful difference in peoples’ lives. equity and respect; giving decision- information. No other organisation makers a sense of the difference that from the public, private or voluntary NHS England reorganisation the Framework could make to families sector provided as much support or if used effectively. advice to help with this consultation. This year we have been actively Our webinars were viewed over 450 influencing the decisions regarding the Specialised services in England times, and feedback from users was reorganisation of the NHS in England, overwhelmingly positive. ensuring that people with rare A major change for the NHS in and genetic conditions are treated England from April 2013 was the Our Director is vice chair of NHS equitably and are able to access the change to national commissioning England’s Public and Patient services that they need. of specialised services. Detailing the Engagement Steering Group and England-wide Service Specifications we influenced NHS England’s We responded to NHS England’s and Commissioning Policies were engagement with patients and patient (previously the NHS Commissioning multidisciplinary groups of clinical groups. We are pleased that from Board) draft mandate, emphasising staff, commissioners and patient or summer 2013, there will be up to four that the intended Outcomes patient group representatives called PPE members on each of the Clinical Framework should provide an Clinical Reference Groups. Reference Groups, strengthening the equitable record of patient outcomes patient voice in the NHS. across the NHS, covering areas We worked hard to nominate and beyond access and socio-economic support our own members for the We are also a member on NHS issues. We were clear in stating that Clinical Reference Groups’ patient and England’s National Commissioning the Framework should not marginalise public engagement (PPE) places. Over Board’s ad hoc Clinical Priorities and disadvantage patients with one-third (40 out of 112) of the PPE Advisory Group. This committee complex, rare and undiagnosed members for 2012-2013 were from had the responsibility of determining conditions. our member groups, giving people national commissioning priorities of with genetic conditions the chance to specialised services for all of England. shape and influence the specialised services they need. 6 Genetic Alliance UK Health service development Daniel and Sophia Nicholls Developing non-invasive Preimplantation genetic ‘I think we would prenatal diagnosis services diagnosis – access for families have had a lot more The technology to allow non-invasive across England heartache if PGD had prenatal diagnosis (NIPD) for a range From April 2013, preimplantation not been an option. I of single gene disorders including genetic diagnosis (PGD) will be Down’s syndrome is advancing nationally commissioned in England. wouldn’t swap a day rapidly, and gauging the opinions Through our PPE role on the Medical of our lives; it’s been a of women who have or are likely to Genetics Clinical Reference Group, we use it, to inform its use is important. advocated for a Commissioning Policy real blessing’ We asked patients and healthcare that is fair and equitable, bringing an Susanna Nicholls, a carrier of professionals what they want from end to the postcode lottery.
Load more

Recommended publications
  • RARE CHROMOSOME DISORDERS the Term, ‘Rare Chromosome Disorders’, Refers to Conditions Which
    INFORMATION SHEET Page 1 COMPLEX LEARNING DIFFICULTIES AND DISABILITIES RESEARCH PROJECT (CLDD) RARE CHROMOSOME DISORDERS The term, ‘rare chromosome disorders’, refers to conditions which: 1. occur due to missing, duplicated or re-arranged chromosome material 2. have a low prevalence rate (thus not including chromosomal disorders such as Down syndrome). Chromosomes are structures found in the nuclei of cells in human bodies. Each chromosome contains thousands of genes which determine how we grow and develop. A typically developing person will have 23 pairs of chromosomes with one member of each pair being inherited from each parent, giving a total of 46 individual chromosomes. Two of these are the sex chromosomes which determine whether we are female (XX) or male (XY). The remaining 44 chromosomes are grouped in 22 pairs, numbered 1 to 22. The arms of a chromosome are called ‘p’ (shorter arm) and ‘q’ (long arm) (see Figure 1); these arms are separated into numerical regions, which in turn are divided into bands and sub-bands. p q Figure 1. Diagram of a chromosome Individually, rare chromosome disorders are extremely uncommon, with some being actually unique; however, collectively rare chromosome disorders make up at least one in every 200 live births, with babies either having symptoms from birth or early childhood, or being carriers of a chromosomal abnormality and experiencing the effects when they try to reproduce in later life (Searle and Hultén, 2009). Recent advances in technology and medical expertise has meant that chromosomes can be viewed at ever increasing magnifications, which is resulting in the detection of more complex defects.
    [Show full text]
  • Lab 17. Chromosomes and Karyotypes: How Do Two Physically Healthy Parents Produce a Child with Down Syndrome and a Second Child
    Lab 17. Chromosomes and Karyotypes: How Do Two Physically Healthy Parents Produce a Child With Down Syndrome and a Second Child With Cri Du Chat Syndrome? Introduction Mendel’s model of inheritance is the basis for modern genetics. This important model can be broken down into four main ideas. First, and foremost, the fundamental unit of inheritance is the gene and alternative versions of a gene (alleles) account for the variation in inheritable characters. Second, an organism inherits two alleles for each character, one from each parent. Third, if the two alleles differ, then one is fully expressed and determines the nature of the specific trait (this version of the gene is called the dominant allele) while the other one has no noticeable effect (this version of the gene is called the recessive allele). Fourth, the two alleles for each character segregate (or separate) during gamete production. Therefore, an egg or a sperm cell only gets one of the two alleles that are present in the somatic cells of the organism. This idea is known as the law of segregation. It was brilliant (or lucky) that Mendel chose plant traits that turned out to have a relatively simple genetic basis. Each trait that he studied is determined by only one gene, and each of these genes only consists of two alleles. These conditions, however, are not met by all inheritable traits. The relationship between traits and genes is not always a simple one. In this investigation, you will use what you know about the relationship between traits and genes to explain how two children from the same family inherited two different genetic disorders.
    [Show full text]
  • Sema4 Noninvasive Prenatal Select
    Sema4 Noninvasive Prenatal Select Noninvasive prenatal testing with targeted genome counting 2 Autosomal trisomies 5 Trisomy 21 (Down syndrome) 6 Trisomy 18 (Edwards syndrome) 7 Trisomy 13 (Patau syndrome) 8 Trisomy 16 9 Trisomy 22 9 Trisomy 15 10 Sex chromosome aneuploidies 12 Monosomy X (Turner syndrome) 13 XXX (Trisomy X) 14 XXY (Klinefelter syndrome) 14 XYY 15 Microdeletions 17 22q11.2 deletion 18 1p36 deletion 20 4p16 deletion (Wolf-Hirschhorn syndrome) 20 5p15 deletion (Cri-du-chat syndrome) 22 15q11.2-q13 deletion (Angelman syndrome) 22 15q11.2-q13 deletion (Prader-Willi syndrome) 24 11q23 deletion (Jacobsen Syndrome) 25 8q24 deletion (Langer-Giedion syndrome) 26 Turnaround time 27 Specimen and shipping requirements 27 2 Noninvasive prenatal testing with targeted genome counting Sema4’s Noninvasive Prenatal Testing (NIPT)- Targeted Genome Counting analyzes genetic information of cell-free DNA (cfDNA) through a simple maternal blood draw to determine the risk for common aneuploidies, sex chromosomal abnormalities, and microdeletions, in addition to fetal gender, as early as nine weeks gestation. The test uses paired-end next-generation sequencing technology to provide higher depth across targeted regions. It also uses a laboratory-specific statistical model to help reduce false positive and false negative rates. The test can be offered to all women with singleton, twins and triplet pregnancies, including egg donor. The conditions offered are shown in below tables. For multiple gestation pregnancies, screening of three conditions
    [Show full text]
  • Trisomy 5P Inverted Duplication & Deletion of 5Pftnwdraft3
    Trisomy 5p: Inverted duplication and deletion of 5p rarechromo.org Inverted duplication with deletion of 5p Inverted duplication with deletion of 5p, known as inv dup del 5p, is a very rare genetic condition in which there is an extra copy of part of the genetic material (DNA) that makes up the body’s 46 chromosomes, and a missing copy of another part. Like most other chromosome disorders, this usually affects development, and sometimes health and behaviour as well. It is likely that both the extra and missing parts of chromosome 5p have an effect, but a lot depends on their position and size. The precise effects of gaining material from a chromosome vary depending on how large the duplication is, how many genes it contains and what those genes do. The same applies to deletions. The effects may not be limited to the genes within the duplicated or deleted piece of chromosome because these genes may interact with other genes on the same chromosome or other chromosomes. Chromosomes usually come in pairs, and we inherit one chromosome from each parent. Of the 46 chromosomes, two are a pair of sex chromosomes: two Xs for a girl and an X and a Y for a boy. The remaining 44 chromosomes are grouped into 22 pairs and are numbered 1 to 22, approximately from largest to smallest. Each chromosome has a short (p) arm (from petit, the French for small) and a long (q) arm. The diagram below shows the short arm. Chromosome 5 Short (p) arm Bands Base pairs 0Mb 5Mb 10Mb 15Mb 20Mb 25Mb 30Mb 35Mb 40Mb 45Mb 48.4Mb Long (q) arm 2 People have 2 copies of chromosome 5 in most of their body cells.
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]
  • Congenital Heart Disease and Chromossomopathies Detected By
    Review Article DOI: 10.1590/0103-0582201432213213 Congenital heart disease and chromossomopathies detected by the karyotype Cardiopatias congênitas e cromossomopatias detectadas por meio do cariótipo Cardiopatías congénitas y anomalías cromosómicas detectadas mediante cariotipo Patrícia Trevisan1, Rafael Fabiano M. Rosa2, Dayane Bohn Koshiyama1, Tatiana Diehl Zen1, Giorgio Adriano Paskulin1, Paulo Ricardo G. Zen1 ABSTRACT Conclusions: Despite all the progress made in recent de- cades in the field of cytogenetic, the karyotype remains an es- Objective: To review the relationship between congenital sential tool in order to evaluate patients with congenital heart heart defects and chromosomal abnormalities detected by disease. The detailed dysmorphological physical examination the karyotype. is of great importance to indicate the need of a karyotype. Data sources: Scientific articles were searched in MED- LINE database, using the descriptors “karyotype” OR Key-words: heart defects, congenital; karyotype; Down “chromosomal” OR “chromosome” AND “heart defects, syndrome; trisomy; chromosome aberrations. congenital”. The research was limited to articles published in English from 1980 on. RESUMO Data synthesis: Congenital heart disease is characterized by an etiologically heterogeneous and not well understood Objetivo: Realizar uma revisão da literatura sobre a group of lesions. Several researchers have evaluated the pres- relação das cardiopatias congênitas com anormalidades ence of chromosomal abnormalities detected by the karyo- cromossômicas detectadas por meio do exame de cariótipo. type in patients with congenital heart disease. However, Fontes de dados: Pesquisaram-se artigos científicos no most of the articles were retrospective studies developed in portal MEDLINE, utilizando-se os descritores “karyotype” Europe and only some of the studied patients had a karyo- OR “chromosomal” OR “chromosome” AND “heart defects, type exam.
    [Show full text]
  • Cri-Du-Chat Syndrome Diagnosed in a 21-Year-Old Woman by Means of Comparative Genomic Hybridization
    Rev. Fac. Med. 2017 Vol. 65 No. 3: 525-9 525 CASE REPORT DOI: http://dx.doi.org/10.15446/revfacmed.v65n3.57414 Cri-du-chat syndrome diagnosed in a 21-year-old woman by means of comparative genomic hybridization Síndrome de cri du chat diagnosticado en mujer de 21 años por hibridación genómica comparativa Received: 15/05/2016. Accepted: 06/08/2016. Wilmar Saldarriaga1 • Laura Collazos-Saa2 • Julián Ramírez-Cheyne2 1 Universidad del Valle - Faculty of Health - Department Morphology - MACOS Research Group - Cali - Colombia. 2 Universidad del Valle - Faculty of Health - Medicine and Surgery - Cali - Colombia. Corresponding author: Wilmar Saldarriaga. Department Morphology, Faculty of Health, Universidad del Valle. Calle 4B No. 36-00, building 116, floor 1, espacio 30. Phone number: +57 2 5285630, ext.: 4030; mobile number: +57 3164461596. Cali. Colombia. Email: [email protected]. | Abstract | entero. La prevalencia va desde 1 por 15 000 habitantes hasta 1 por 50 000 habitantes. Su diagnóstico se puede confirmar con cariotipo The cri-du-chat syndrome is caused by a deletion on the short con bandas G de alta resolución, hibridación fluorescente in situ o arm of chromosome number 5. The size of genetic material loss hibridación genómica comparativa por microarreglos (HGCm); este varies from the 5p15.2 region only to the whole arm. Prevalence se sospecha en infantes con un llanto similar al maullido de un gato, rates range between 1:15000 and 1:50000 live births. Diagnosis fascies dismórficas, hipotonía y retardo del desarrollo psicomotor; is suspected on infants with a high-pitched (cat-like) cry, facial sin embargo, en los adultos afectados los hallazgos fenotípicos son dysmorfism, hypotonia and delayed psychomotor development.
    [Show full text]
  • Author's Personal Copy
    Author's personal copy 534 Z. Schlegel et al. du chromosome 5. L’atteinte oculaire chez les patients porteurs de trisomie 5 est très rare. D’après nos connaissances seulement, deux cas ont été décrits jusqu’à présent. Le cas actuel contribue à la description de la présentation oculaire en plus de phénotype clinique indéniable du syndrome de de novo trisomie partielle 5. © 2009 Elsevier Masson SAS. Tous droits réservés. Introduction Observation Trisomy of the short arm of chromosome 5 is a clinically dis- History and clinical observation cernible but very infrequent syndrome with characteristic features, considered by Stoll et al. [1] as the reverse type We describe a male Malagasy infant with a small super- of cri-du-chat syndrome. Lejeune et al. [2] first described numerary marker chromosome 5 (sSMC) present in 80% of this chromosomal abnormality in 1964; later a description metaphases. The child was born at 33 weeks gestation after was provided by Gustavson et al. [3] in 1988. The Office of in vitro fertilization and embryo transfer (IVF-ET) to the Rare Diseases (ORD) of the National Institutes of Health (NIH) 37-year-old mother with a history of sterility due to Fal- lists chromosome 5 trisomy as a ‘‘rare disease’’; this means lopian tube obstruction. The boy was born as a result of that chromosome 5 trisomy with both its subtypes, 5p and the first successful pregnancy after two unsuccessful IVF-ET 5q, affects fewer than 200,000 people in the US population. attempts with two unrelated and healthy parents. Its incidence and prevalence are difficult to establish.
    [Show full text]
  • Panorama™ Non-Invasive Prenatal Screening for Microdeletion Syndromes
    NON-INVASIVE PRENATAL SCREENING FOR MICRODELETION SYNDROMES HALL 1 PANORAMA™ NON-INVASIVE PRENATAL SCREENING FOR MICRODELETION SYNDROMES MEGAN P. HALL, PH.D. INTRODUCTION PanoramaTM is a non-invasive prenatal screening test for fetal chromosomal anomalies. The screening test analyzes fetal cell-free DNA (cfDNA) isolated from maternal plasma and can be performed as early as 9 weeks of gestation with high accuracy. Panorama was originally designed to screen for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome), Monosomy X (Turner syndrome), sex chromosome trisomies, triploidy and, if requested, fetal sex (1-5). Recently, the clinical scope of Panorama was expanded to include screening for five microdeletion syndromes. This Panorama Extended Panel now screens for the 22q11.2 deletion (DiGeorge), 1p36 deletion, Cri-du-chat, Prader-Willi, and Angelman deletions. Validation studies have demonstrated sensitivities of greater than 93% and specificities of greater than 99% for each microdeletion condition. MICRODELETION PREVALENCE AND TRADITIONAL MICRODELETION DETECTION Clinically relevant microdeletions and microduplications are more common than previously thought, occurring in up to 1 in 60 pregnancies, and can occur in pregnancies lacking ultrasound anomalies (6). The combined at-birth incidence of the 5 microdeletion syndromes covered by this screening test is approximately 1 in 1,000 (7-11), approaching the overall rate observed for Down syndrome (12). The most common microdeletion, 22q11.2 deletion, is more common than Edwards syndrome and Patau syndrome combined, and is more common than cystic fibrosis (Figure 1)(10,12,13). Further, the risk for microdeletions is independent of maternal age, unlike whole chromosome aneuploidies like Trisomy 21 (Down syndrome) that are more prevalent in women of advanced maternal age.
    [Show full text]
  • Ring Chromosome 5 with Dental Anomalies
    PEDIATRICDENTISTRY/Copyright -~ 1981 by The American Academyof Pedodontics/Vol. 3, No. 4 CASE Ring chromosome 5 with dental anomalies Katherine Kula, DMDShivanand Patil, PhD James Hanson, MD Arthur Nowak, DMDHans Zellweger, MD Abstract Although ring chromosomesare observed in ahnost all manent molars is reported in one case2 autosomalgroups in man, they are rare. Wedescribe a male Although,~ some patients survive to adulthood) patient exldbiting cd du chat syndromein which most patients die in infancy due to severe respiratory cytogenetic studies demonstratethe presonse of a ring and feeding problems2 chromosome5. Deletion o£ the ring chromosome5 is found between the p15 and q35 bands. Dental, medical and Diagnosis is based on clinical features, abnormal cytogenetic findings are comparedto other ring chromosome crying during infancy, chromosomal studies, and der- 5 cases descMbedin literature. matoglyphic features. Diagnosis based soley on clini- cal features is difficult in somecases due to phenoty- Introduetion pic variability and to characteristics changing with Cri du chat syndrome, first described in 1963,~ is age. Clinical features are used, however, as indications characterized by a shrill high cry similar to that of a for confLrmatory chromosomal studiesY young cat. The cry is attributed to a hypotonic, dys- Cri du chat syndromeis usually attributed to a par- morphic larynx noted in some patients. ~ The cry may tial deletion, either terminal or interstitial, of the not be pathognomonic of the syndrome since it is ab- short arm of chromosome57 in the area of p14 to p15 sent in some patients and is reported in other chromo- band?~ The most commonly reported cause is de novo somal abnormalities? deletion occurring in approximately 85 percent of the The~,~ following traits may be found during infancy: cases, m~There are eight reported cases of ring chromo- microcephaly, round facies, apparent ocular hypertel- someu,l~ 5.
    [Show full text]
  • Neurological Syndromes
    Neurological Syndromes J. Gordon Millichap Neurological Syndromes A Clinical Guide to Symptoms and Diagnosis J. Gordon Millichap, MD., FRCP Professor Emeritus of Pediatrics and Neurology Northwestern University Feinberg School of Medicine Chicago, IL, USA Pediatric Neurologist Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago , IL , USA ISBN 978-1-4614-7785-3 ISBN 978-1-4614-7786-0 (eBook) DOI 10.1007/978-1-4614-7786-0 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013943276 © Springer Science+Business Media New York 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]